Ohio State Navbar

Clinical Trials


 

 

If you would like more information or are interested in referring a patient to one of these trials, click on the PI's name to generate a contact email or call The James Line at 1-800-293-5066.  To search all cancer clinical trials available at Ohio State, visit cancer.osu.edu.

Featured Trials
  • Phase I/II Dose-Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
    (OSU-16120) Maura Gillison, MD, PhD
     
  • Phase Ib Dose-Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PLX51107 in Subjects With Advanced Malignancies
    (OSU-16056) Robert Wesolowski, MD 
Recently Opened Trials
 

Breast

  • Compassionate Use Neratinib for a Patient With HER2-Positive Metastatic Breast Cancer
    (OSU-16208) Maryam Lustberg, MD
     
  • Phase Ib Study to Assess the Safety, Tolerability and Clinical Activity of Gedatolisib in Combination With Palbociclib and Either Letrozole or Fulvestrant in Women With Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)
    (OSU-16052) Robert Wesolowski, MD
     

Gastrointestinal

  • Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
    (OSU-15241) Kristen Ciombor, MD
     

Genitourinary

  • Androgen Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
    (RTOG-0924) Dayssy Diaz Pardo, MD
     
  • Phase Ib, Multicenter, Open-Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder
    (OSU-16090) Kamal Pohar, MD


Melanoma

  • Randomized, Controlled, Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
    (OSU-16073) Harrison Howard, MD


Thoracic

  • Phase Ib Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
    (OSU-16155) Erin Bertino, MD
Immune Therapy Trials 
 

Breast

  • Phase I, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
    OSU-15281 (Robert Wesolowski, MD)

Gastrointestinal

  • Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
    (OSU-15169) Kristen Ciombor, MD
     
  • Phase II Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
    (OSU-14006) Richard Goldberg, MD
     
  • Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
    (OSU-15298) Richard Goldberg, MD
  • Phase I, Open-Label, Multiple-Ascending-Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
    (OSU-13257) John Hays, MD, PhD

Genitourinary

  • Phase I Study of (Cabozantinib) Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    OSU-15150 (Amir Mortazavi, MD
     
  • Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti−Pd-L1 Antibody) vs. Observation as Adjuvant Therapy in Patients With Pd-L1−Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy
    (OSU-16078) Amir Mortazavi, MD
     
  • Phase III, Multinational, Randomized, Open-label, Parallel-Arm Study of Avelumab (Msb0010718c) in Combination With Axitinib (Inlyta®) vs. Sunitinib (Sutent®) Monotherapy in the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
    (OSU-15292) Thomas Olencki, DO
     

Gynecologic

  • Phase I/II Study of Chemo-Immunotherapy With Toll-Like Receptor 8 Agonist Motolimod (VTX-2337) and Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
    (OSU-15125) David O’Malley, MD


Head and Neck

  • Phase III, Randomized, Open-Label, Multicenter, Global Study of MEDI4736 Alone or in Combination With Tremelimumab vs. Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
    (OSU-15210) Maura Gillison, MD, PhD
     
  • Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
    (OSU-16120) Maura Gillison, MD, PhD
     
  • Randomized, Phase III Trial of Cisplatin-Based Chemotherapy (CRT) +/- Nivolumab (ANTI-PD-1) in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (with Phase I Lead in)
    (RTOG-3504) Maura Gillison, MD, PhD


Melanoma

  • Randomized, Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
    (ECOG-EA6134) Joanne Jeter, MD

    Phase III, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab vs. Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence
    (OSU-15130) Kari Kendra, MD, PhD

    Phase III Randomized Trial Comparing Physician/Patient Choice of Either High-Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High-Risk Resected Melanoma
    (SWOG- S1404) Kari Kendra, MD, PhD

Neuroendocrine

  • Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
    OSU-15244 (Manisha Shah, MD)

Thoracic

  • Phase Ib Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors
    (OSU-15219) Erin Bertino, MD
     
  • Phase Ib Open-Label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
    (OSU-15265) Greg Otterson, MD
     
  • Phase I, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel/Carboplatin in Stage IIIb/IV Non-Small Cell Lung Cancer or Nab- Paclitaxel in Recurrent Metastatic Breast Cancer
    (OSU -14250) Greg Otterson, MD
     
  • Randomized, Multicenter, Double-Blind, Phase III Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-Based First-Line Chemotherapy
    (OSU-15171) Greg Otterson, MD
     
  • Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer
    (OSU-16074) Greg Otterson, MD
     
  • Open-Label, Single-Arm, Phase II Study of Nivolumab in Combination With Ipilimumab as First-Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
    (OSU-16086) Greg Otterson, MD
     
  • Open-Label, Randomized, Phase III Trial of Nivolumab, or Nivolumab + Ipilimumab, or Nivolumab + Platinum Doublet Chemotherapy vs. Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
    (OSU-15127) Greg Otterson, MD

 

Updated: 10/31/16

 

 

© 2016 The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute
460 W. 10th Avenue
Columbus, Ohio 43210

cancer.osu.edu

Jamesline Blog  Facebook  Twitter  LinkedIn  Google+  Instagram  YouTube  Pinterest  Cancer Connect